Enanta Posts 81-Cent Quarterly Loss as Patent Setback Clouds Pipeline
ENTA is trading near its 52-week low of $10.05 (6.1% above the low).
Summary
Enanta reported a fourth-quarter loss of 81 cents per share, with a 4Q loss of $23.7M on revenue of $12.9M. That follows a Q3 net loss of $19.5M disclosed in the August 10-Q, so the company remains unprofitable while funding its RSV and immunology programs, and it reported an FY2026 net loss of $68.2M. The loss lands two weeks after the EU Unified Patent Court invalidated its '265 patent and dismissed its infringement action against Pfizer, removing a key legal lever. With a $75M at-the-market program already in place and a $150M shelf on file, dilution risk stays live for a company of this size.
At the time of this announcement, ENTA was trading at $10.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $312.2M. The 52-week trading range was $10.05 to $17.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.